Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model

Fatima Amanat,a,b Shirin Strohmeier,a Raveen Rathnasinghe,a,b,c Michael Schotsaert,a,c Lynda Coughlan,a Adolfo García-Sastre,a,c,d,e Florian Krammera

aDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
bGraduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA
cGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
dDepartment of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA
eThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA

ABSTRACT The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the prime target for vaccine development. The spike protein mediates both binding to host cells and membrane fusion and is also so far the only known viral target of neutralizing antibodies. Coronavirus spike proteins are large trimers that are relatively unstable, a feature that might be enhanced by the presence of a polybasic cleavage site in SARS-CoV-2 spike. Exchange of K986 and V987 for prolines has been shown to stabilize the trimers of SARS-CoV-1 and the Middle East respiratory syndrome coronavirus spike proteins. Here, we test multiple versions of a soluble spike protein for their immunogenicity and protective effect against SARS-CoV-2 challenge in a mouse model that transiently expresses human angiotensin-converting enzyme 2 via adenovirus transduction. Variants tested include spike proteins with a deleted polybasic cleavage site, proline mutations, or a combination thereof, besides the wild-type protein. While all versions of the protein were able to induce neutralizing antibodies, only the antigen with both a deleted cleavage site and the K986P and V987P (PP) mutations completely protected from challenge in this mouse model.

IMPORTANCE A vaccine for SARS-CoV-2 is urgently needed. A better understanding of antigen design and attributes that vaccine candidates need to have to induce protective immunity is of high importance. The data presented here validate the choice of antigens that contain the PP mutations and suggest that deletion of the polybasic cleavage site may lead to a further-optimized design.

KEYWORDS COVID-19, SARS-CoV-2, spike, vaccine

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 in China and has since caused the coronavirus disease 2019 (COVID-19) pandemic (1–3). Vaccines are an urgently needed countermeasure to the virus. Vaccine candidates have been moved at unprecedented speed through the pipeline, with the first phase III trials already taking place in the summer of 2020, only half a year after discovery of the virus sequence. From studies on SARS-CoV-1 and Middle East respiratory syndrome CoV (MERS-CoV), it was clear that the spike protein of the virus is the best target for vaccine development (4–6). Most CoVs have only one large surface glycoprotein (a minority also have a hemagglutinin [HA] esterase) that is used by the virus to attach to the host cell and trigger the fusion of viral and cellular membranes. The spike protein of SARS-CoV-2, like the one of SARS-CoV-1, binds to human angiotensin-converting enzyme 2 (ACE2) on the surface of host cells, which is the entry point for the virus into the host cell and the target for neutralizing antibodies [1]–[4]. In addition, the spike protein mediates membrane fusion and is also the only known target of neutralizing antibodies [1,5]. The spike protein is a large glycoprotein with a molecular weight of approximately 116 kDa that is responsible for binding to ACE2 on host cells and for mediating membrane fusion [6]. The spike protein is composed of two subunits, the S1 subunit, which mediates binding to ACE2, and the S2 subunit, which mediates membrane fusion [7]. The S1 subunit consists of two domains, the N-terminal domain (NTD) and the C-terminal domain (CTD) [6,8]. The NTD binds to ACE2 [9], whereas the CTD contains the receptor-binding domain (RBD) [10]. The RBD is responsible for binding to ACE2 and is the target for neutralizing antibodies [1,5]. The S2 subunit consists of two domains, the fusion peptide (FP) and the stalk [6]. The FP is responsible for membrane fusion and is the target for neutralizing antibodies [2,11]. The stalk is a flexible structure that connects the S1 and S2 subunits [6]. The S2 subunit can be further divided into two subdomains, the S2a subdomain, which contains the fusion peptide, and the S2b subdomain, which is responsible for membrane fusion [6]. The S2 subunit is responsible for membrane fusion and is the target for neutralizing antibodies [2,11]. The S2 subunit can be further divided into two subdomains, the S2a subdomain, which contains the fusion peptide, and the S2b subdomain, which is responsible for membrane fusion [6]. The S2 subunit is responsible for membrane fusion and is the target for neutralizing antibodies [2,11].
enzyme 2 (hACE2) (7–9). In order to be able to trigger fusion, the spike protein has to be cleaved into the S1 and S2 subunits (10–12). Additionally, a site in S2 (S2') that has to be cleaved to activate the fusion machinery has been reported as well (13). While the spike of SARS-CoV-1 contains a single basic amino acid at the cleavage site between S1 and S2, SARS-CoV-2 has a polybasic motif that can be activated by furin-like proteases (10–12), analogously to the HA of highly pathogenic H5 and H7 avian influenza viruses. In addition, it has been reported that the activated spike protein of CoVs is relatively unstable and that multiple conformations might exist, of which not all may present neutralizing epitopes to the immune system. For SARS-CoV-1- and MERS-CoV-stabilizing mutations—a pair of prolines replacing K986 and V987 in S2—have been described (14), and a beneficial effect on stability has also been shown for SARS-CoV-2 (9). Here, we set out to investigate if including these stabilizing mutations, removing the cleavage site between S1 and S2, or combining the two strategies to stabilize the spike would increase its immunogenicity and protective effect in a mouse model that transiently expresses hACE2 via adenovirus (AdV) transduction (15). This information is important since it can help to optimize vaccine candidates, especially improved versions of vaccines that might be licensed at a later point in time.

RESULTS

Construct design and recombinant protein expression. The sequence based on the S gene of SARS-CoV-2 strain Wuhan-1 was initially codon optimized for mammalian cell expression. The wild-type signal peptide and ectodomain (amino acids 1 to 1213) were fused to a T4 foldon trimerization domain followed by a hexahistidine tag to facilitate purification. This construct was termed wild type (WT). Additional constructs were generated, including one in which the polybasic cleavage site (RRAR) was replaced by a single alanine (termed ΔCS), one in which K986 and V987 in the S2 subunit were mutated to prolines (PP), and one in which both modifications were combined (ΔCS-PP) (Fig. 1A to C). The proteins were then expressed in a baculovirus expression system and purified. At first inspection by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue staining, all four constructs appeared similar, with a major clean band at approximately 180 kDa (Fig. 1E). When Western blotting was performed, additional bands were detected in the lanes with the WT, PP, and ΔCS-PP constructs, suggesting cleavage of a fraction of the protein. However, the patterns of the bands were different for the three constructs. For the WT, the most prominent detected smaller band ran at 80 kDa, was visualized with an antibody recognizing the C-terminal hexahistidine tag, and likely represents S2 (Fig. 1F). The two constructs containing the PP mutations also produced an additional band at approximately 40 kDa (Fig. 1E), potentially representing a fragment downstream of S2'. While in general, these bands were invisible by SDS-PAGE and therefore likely represent only a tiny fraction of the purified spike protein, they might indicate vulnerability to proteolytic digest of the antigen in vivo. All constructs were also recognized in a similar manner by monoclonal antibody (MAb) CR3022 (16, 17), an antibody that binds to the receptor binding domain (RBD) (Fig. 1F).

All versions of the recombinant spike protein induce robust immune responses in mice. To test the immunogenicity of the four spike constructs, all proteins were used in a simple prime-boost study in mice (Fig. 2A). Animals were injected intramuscularly (i.m.) with 3 μg of spike protein adjuvanted with AddaVax (a generic version of the oil-in-water adjuvant MF59) twice in a 3-week interval. A control group received an irrelevant immunogen, recombinant influenza virus hemagglutinin (HA), also expressed in insect cells, with AddaVax. Mice were bled 3 weeks after the priming and 4 weeks after the boost to assess the immune response that they mounted to the vaccine (Fig. 2B). To determine antibody levels to the RBD, we performed enzyme-linked immunosorbent assays (ELISAs) against the recombinant, mammalian cell-expressed RBD (18, 19). All animals (except the negative control animals) made anti-RBD responses after the priming, but they were higher in the ΔCS and ΔCS-PP groups than in the WT or PP group (Fig. 2C). The booster dose increased antibodies to the RBD significantly, but the same
pattern persisted (Fig. 2D). Interestingly, the ΔCS-PP group showed very homogenous responses compared to those of the other groups, in which there was more spread between the animals. In addition, we performed cell-based ELISAs with Vero cells infected with SARS-CoV-2 as the target. While all groups showed good reactivity, similar patterns emerged in which ΔCS and ΔCS-PP groups showed higher reactivity than WT and PP groups (Fig. 2E). Finally, we performed microneutralization assays with authentic SARS-CoV-2 (20). Here, the WT, PP, and ΔCS groups showed similar levels of neutralization, while the ΔCS-PP group of animals had higher serum neutralization titers (Fig. 2F).

Vaccination with recombinant S protein variants protects mice from challenge with SARS-CoV-2. In order to perform challenge studies, mice were sensitized to infection with SARS-CoV-2 by intranasal (i.n.) transduction with an adenovirus expressing hACE2 (AdV-hACE2), using a treatment regimen described previously (Fig. 2A) (15, 21, 22). They were then challenged with 10⁵ plaque forming units (PFU) of SARS-CoV-2 and monitored for weight loss and mortality for 14 days. Additional animals were euthanized on day 2 and day 4 to harvest lungs for histopathological assessment and immunohistochemistry (IHC) and on day 2 and day 5 to measure virus titers in the lung. After challenge, all groups lost weight, trending with the negative-control group (irrelevant HA protein vaccination), except for the ΔCS-PP group, which displayed minimal weight loss (Fig. 3A). Only on days 4 to 6, the WT, PP, and ΔCS groups showed a trend toward less weight loss than the control group. However, all animals recovered, and by day 14, no mortality was observed. Lung titers on day 2 suggested low virus replication in the WT, PP, and ΔCS groups, with some animals having no detectable virus and no presence of replication-competent virus in the ΔCS-PP animals (Fig. 3B). Two of the control animals showed high virus replication, while virus could not be recovered from the third animal.
No virus could be detected in any of the vaccinated groups on day 5, while all three controls still had detectable virus in the range of 10⁴ to 10⁵ PFU (Fig. 3C).

**Lung immunohistochemistry and pathology.** Lungs were harvested on days 2 and 4 postchallenge. Samples from both days were used for immunohistochemistry to detect viral nucleoprotein antigen. Viral antigen was detectable in all groups on day 2 as well as day 4 postinfection (Fig. 3D). However, the ΔCS-PP group showed very few positive cells, especially on day 4, while antigen was more widespread in all other groups. These results correlate well with the viral lung titers reported above. The samples were also stained with hematoxylin and eosin (H&E) and scored for lung pathology by a qualified veterinary pathologist using a composite score with a maximum value of 24 (Fig. 4A and C). At day 2 postinfection with SARS-CoV-2, all mice were determined to exhibit histopathological lesions typical of interstitial pneumonia, with more severe alveolar inflammation in the WT group. Alveolar congestion and edema were also more pronounced in S-vaccinated groups than in groups vaccinated with the irrelevant control HA immunogen. At this time point, the overall pathology score was lowest for the irrelevant HA control group, followed by ΔCS-PP<PP<ΔCS<wild type (Fig. 4A). On day 4, all groups showed mild-to-moderate pathology scores, reduced in severity compared with those on day 2.
Observations included perivascular, bronchial, and alveolar inflammation, as well as mild-to-moderate congestion or edema. Scores were slightly higher in vaccinated than in control animals, which may reflect the infiltration of CoV-2 antigen-specific immune cells into the lung, which are absent in the irrelevant HA-immunized control mice (Fig. 4C and D).

**DISCUSSION**

The spike protein of SARS-CoV-2 was selected early on as a target for vaccine development, based on experience with SARS-CoV-1 and MERS-CoV (6). The coronavirus spike protein is known to be relatively labile, and in addition to this inherent property, the SARS-CoV-2 spike protein contains a polybasic cleavage site between S1 and S2. Work on SARS-CoV-1 and MERS-CoV had shown that introducing two prolines in positions 986 and 987 (SARS-CoV-2 numbering) improves stability and expression (14). In addition, removal of polybasic cleavage sites has been shown to stabilize hemagglutinin (HA) proteins of highly...
pathogenic influenza viruses. In this study, we tested different versions of the protein either lacking the polybasic cleavage site or including the stabilizing PP mutations or both. While vaccination with all constructs induced neutralizing antibodies and led to control of virus replication in the lung, we observed notable differences. Removing the polybasic cleavage site did increase the humoral immune response in ELISAs. Since we did not observe cleavage of the majority of the protein when it was purified, even with the polybasic cleavage site present (although some cleavage could be observed), we speculate that removal of the site might make the protein more stable in vivo postvaccination. Longer stability may lead to stronger and potentially more uniform immune responses. The combination of deleting the polybasic cleavage site plus introducing the PP mutations performed best, also in terms of protection of mice from weight loss. It is important to note that all versions of the protein tested had a third stabilizing element present, which is a trimerization domain. This trimerization domain might have also increased stability and immunogenicity.

Current leading vaccine candidates in clinical trials and licensed/authorized vaccines include virus-vectored and mRNA vaccines as well as inactivated vaccines and recombinant protein vaccines (23). The ChAdOx-based vaccine candidate developed by AstraZeneca, as well as the CanSino- and Gamaleya-vectored candidates, use a wild-type version of the spike protein (24–26). The same is of course true for the inactivated vaccines produced by Sinovac and Sinopharm (27, 28). Moderna’s and Pfizer’s mRNA vaccines are based on a spike construct that includes the PP mutations but features a wild-type cleavage site (29, 30). It is currently unclear if addition of the modifications shown here to enhance the immunogenicity of recombinant protein spike antigens would also enhance the immunogenicity of these constructs. However, it might be worth testing if these vaccine candidates can be improved by our strategy as well. Of note, one study in nonhuman primates with adenovirus 26-vectored vaccine candidates (from J&J) expressing different versions of the spike protein also showed that the ΔCS-PP candidate (although including the transmembrane domain) performed best, and this candidate was moved forward into clinical trials and is expected to be authorized/licensed soon (31). Similarly, Novavax is using a recombinant spike construct that features ΔCS-PP and, when adjuvanted, induced high neutralization titers in humans in a phase I clinical trial (32).
While vaccination with all constructs led to various degrees of control of virus replication, histopathology scores, especially on day 2 after challenge, were above those of the negative-control animals. The histopathology scores higher than those of the negative controls are likely due to an antigen-specific immune response and not due to the adenovirus transduction, which in general leads to only transient and mild inflammation (and would also be present in the control group) (15, 21). This is also evidenced by significantly reduced weight loss in the ΔCS-PP group as well as complete control of virus replication, despite increased lung histopathology scores. However, future studies with recombinant protein vaccines that are routed for clinical testing will need to assess this increase in lung pathology in more detail. Other caveats that need to be discussed are the variability introduced by the adenovirus transduction step and the many cell types that are transduced by human adenovirus 5 (HAdV-C5) in mice, including cell types that do not express ACE2 in humans (33–35). The first point may explain why some animals did not have viral titers on day 2, while the second point may explain why, despite high neutralization titers, protection was suboptimal in several of the groups.

Recombinant protein vaccines including the spike ectodomain (36, 37) and membrane-extracted spike (38), as well as S1 (39) and the RBD (40), have been tested for SARS-CoV-1, and several studies show good efficacy against challenge in animal models. It is, therefore, not surprising that similar constructs for SARS-CoV-2 also provided protection. While our goal was not vaccine development but studying the effect of stabilizing elements on the immunogenicity of the spike protein, Sanofi Pasteur has announced the development of a recombinant protein-based SARS-CoV-2 vaccine, and several additional recombinant protein vaccine candidates are being developed with Novavax’ candidate expected to be licensed/authorized soon. Our data show that this approach might be effective.

MATERIALS AND METHODS

Cells and viruses. Vero.E6 cells (ATCC CRL-1586, clone E6) were maintained in culture using Dulbecco’s modified Eagle medium (Gibco), which was supplemented with an antibiotic-antimycotic mixture (100 U/ml penicillin–100 μg/ml streptomycin–0.25 μg/ml amphotericin B) (Gibco; 15240062) and 10% fetal bovine serum (FBS; Corning). SARS-CoV-2 (isolate USA-WA1/2020; BEI Resources, catalog no. NR-52281) was grown in Vero.E6 cells as previously described and was used for the in vivo challenge (20). A viral seed stock for a nonreplicating human adenovirus type 5 (HAdV-C5) vector expressing the human ACE2 receptor was obtained from the Iowa Viral Vector Core Facility. High-titer AdV-hACE2 stocks were amplified in TRex-293 cells and purified by CsCl ultracentrifugation, and infectious titers were determined by 50% tissue culture infectious dose (TCID₅₀) analysis, with adjustment for PFU titers using the Kärber statistical method, as described previously (41).

Recombinant proteins. All recombinant proteins were expressed and purified using the baculovirus expression system, as previously described (18, 42, 43). Different versions of the spike protein of SARS-CoV-2 (GenBank accession no. MN908947.3 for the original sequence, accession no. MT380725 for the codon-optimized ΔCS-PP construct) were expressed to assess immunogenicity. PP indicates that two stabilizing prolines were induced at K986 and K987. ΔCS indicates that the cleavage site of the spike protein was removed by deletion of the arginine residues (RRAR to just A). The HA was also produced in the baculovirus expression system, as with the spike variants.

SDS-PAGE and Western blotting. One microgram of each respective protein was mixed at a 1:1 ratio with 2 × Laemmli buffer (Bio-Rad), which was supplemented with 2% β-mercaptoethanol (Fisher Scientific). The samples were heated at 90°C for 10 min and loaded onto a 4 to 20% precast polyacrylamide gel (Bio-Rad). The gel was stained with SimplyBlue SafeStain (Invitrogen) for 1 h and then destained with water for a few hours. For Western blotting, the same process as mentioned above was used. After the gel was run, the gel was transferred onto a nitrocellulose membrane, as described previously (42). The membrane was blocked with phosphate-buffered saline (PBS; Gibco) containing 3% nonfat milk (AmericanBio; catalog no. AB10109-01000) for an hour at room temperature on an orbital shaker. Next, primary antibody was prepared in PBS containing 1% nonfat milk using antihexahistidine antibody (TaKaRa Bio; catalog no. 631212) at a dilution of 1:3,000. The membrane was stained with primary antibody solution for 1 h at room temperature. The membrane was washed three times with PBS containing 0.1% Tween 20 (PBS-T; Fisher Scientific). The secondary solution was prepared with 1% nonfat milk in PBS-T using anti-mouse IgG (whole molecule)–alkaline phosphatase (AP) antibody produced in goat (Sigma-Aldrich) at a dilution of 1:3,000. The membrane was developed using an AP conjugate substrate kit (catalog no. 1706432; Bio-Rad).

ELISA. Ninety-six-well plates (Immulum 4 HBX; ThermoFisher Scientific) were coated with the recombinant RBD at a concentration of 2 μg/ml, with 50 μl/well overnight. The RBD protein was produced in 293F cells and purified using Ni-nitrilotriacetic acid (Ni-NTA) resin, and this procedure has been described in detail previously (19). The next morning, coating solution was removed and plates were

March/April 2021 Volume 12 Issue 2 e02648-20 mbio.asm.org
blocked with 100 μl of 3% nonfat milk (AmericanBio; catalog no. AB10109-01000) prepared in PBS-T for 1 h at room temperature (RT). Serum samples from vaccinated mice were tested in an ELISA, starting at a dilution of 1:50, and subsequent 3-fold dilutions were performed. Serum samples were prepared in PBS-T containing 1% nonfat milk, and the plates were incubated with the serum samples for 2 h at RT. Next, plates were washed with 200 μl of PBS-T three times. Anti-mouse IgG conjugated to horseradish peroxidase (Rockland; catalog no. 610-4302) was used at a concentration of 1:3,000 in PBS-T with 1% nonfat milk, and 100 μl was added to each well for 1 h at RT. Plates were then washed again with 200 μl of PBS-T and patted dry with a paper towel. Developing solution was prepared in sterile water (WFI; Gibco) using SigmaFast OPD (o-phenylenediamine dihydrochloride, catalog no. P9187; Sigma-Aldrich), and 100 μl was added to each well for a total of 10 min. Next, the reaction was stopped with 50 μl of 3 M hydrochloric acid, and absorbance was measured at 490 nm (OD490) using a Synergy 4 (BioTek) plate reader. Data were analyzed using GraphPad Prism 7, and area under the curve (AUC) values were measured and graphed (18). An AUC of 0.05 was assigned to negative values for data analysis purposes. ELISAs with CR3022 against the different versions of recombinant protein were performed in a similar fashion but with an anti-human IgG secondary antibody.

To perform an ELISA on infected cells, Vero.E6 cells were seeded at 20,000 cells per well in a 96-well cell culture plate a day and infected at a multiplicity of infection of 0.1 for 24 h with SARS-CoV-2 (isolate USA-WA1/2020, catalog no. NR-52281; BEI Resources). The cells were fixed with 10% formaldehyde (Polysciences) for 24 h, after which the ELISA procedure mentioned above was performed using serum from each vaccinated animal.

Mouse vaccinations and challenge. All animal procedures were performed by adhering to the Institutional Animal Care and Use Committee (IACUC) guidelines. Six- to 8-week-old female BALB/c mice (Jackson Laboratories) were immunized intramuscularly with 3 μg of recombinant protein per mouse with an adjuvant. Adjuvant was an intramuscular solution of 3 μg of each respective protein with adjuvant. Mice were bled 3 weeks after the priming regimen and were also bled 4 weeks after the booster regimen. Another 4 weeks later, SARS-CoV-2 was administered intranasally to each mouse in a final volume of 50 μl per site. Adhering to institutional guidelines, a mixture containing 0.15 mg/kg of body weight ketamine and 0.03 mg/kg xylazine in water was used as anesthesia for mouse experiments, and intranasal infection was performed under anesthesia.

Five days postadministration of AdV-hACE2, mice were infected with 10^6 PFU of SARS-CoV-2. On day 2 and day 5, mice were euthanized using humane methods, and the whole lung was dissected from each mouse. Mice were sacrificed for measuring viral titers in the lung as well as to see pathological changes in the lungs. Lungs were homogenized using a BeadBlaster 24 (Benchmark) homogenizer, after which the supernatant was clarified by centrifugation at 14,000 × g for 10 min. The experimental design was adapted from earlier reported work (15, 44). The remaining mice were weighed daily for 14 days.

Microneutralization assays. We used a very detailed protocol that we published earlier for measuring neutralizing antibody in serum samples (18, 20). Briefly, Vero.E6 cells were seeded at a density of 20,000 cells per well in a 96-well cell culture plate. Serum samples were heat inactivated for 1 h at 56°C. Serial dilutions starting at 1:10 were prepared in 1× minimal essential medium (MEM) supplemented with 1% FBS. The remaining steps of the assay were performed in a biosafety level 3 (BSL3) facility. Six hundred TCID₅₀ of virus in 80 μl was added to 80 μl of each serum dilution. The serum-virus mixture was incubated at room temperature for 1 h. After 1 h, medium from the cells was removed and 120 μl of the serum-virus mixture was added onto the cells. The cells were incubated for 1 h in a 37°C incubator. After 1 h, all of the serum-virus mixture was removed. One hundred microliters of each corresponding serum dilution was added onto the cells, and 100 μl of 1× MEM was added to the cells as well. The cells were incubated at 37°C for 2 days. After 2 days, cells were fixed with 10% formaldehyde (Polysciences). The next day, cells were stained with an antinucleoprotein antibody (ThermoFisher; catalog no. PA5-81794) according to our published protocol (20). The 50% inhibitory dilution (ID₅₀) for each serum was calculated, and the data were graphed. Negative samples were reported as half of the limit of detection (ID₅₀ of 5).

Plaque assays. Four hundred thousand Vero.E6 cells were plated the day before the plaque assay was performed. All assays using SARS-CoV-2 were performed in the BSL3 facility according to institutional guidelines. To assess viral titers in the lung, plaque assays were performed using lung homogenates. Dilutions of lung homogenates were prepared starting from 10^{-1} to 10^{-4} in 1× MEM supplemented with 2% FBS. Medium was removed from the cells, and each dilution was added to the cells. The cells were incubated in a humidified incubator at 37°C for 1 h. Next, the virus was removed, and cells were overlaid with 2× MEM supplemented with 2% Oxoid agar (final concentration of 0.7%) as well as 4% FBS. The cells were incubated at 37°C for 72 h, after which cells were fixed with 1 ml of 10% formalin (Polysciences) for 24 h to ensure inactivation of the virus. Crystal violet was used to visualize the plaques. The limit of detection was 250.

Histology and immunohistochemistry. Mice were subjected to terminal anesthesia and euthanasia, performed by exsanguination of the femoral artery, before lungs were flushed/inflated with 10% formaldehyde by injecting a 19-gauge needle through the trachea on day 4 for immunohistochemistry.Fixed lungs were sent to a commercial entity, Histowiz, for paraffin embedding, tissue analysis, and scoring by an independent veterinary pathologist. Hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining were performed. IHC staining was performed using an anti-SARS-CoV nucleoprotein antibody (Novus Biologicals; catalog no. NB100-56576). Histology and IHC for day 2 samples were performed on only half of the lung, which was dissected and cut in half from sacrificed mice. The other half of the lung was used for quantification of the virus, as mentioned above.
Scores were assigned by the pathologist based on six parameters: perivascular inflammation, bronchial/bronchioal epithelial degeneration/necrosis, bronchial/alveolar inflammation, perivascular inflammation, bronchial/alveolar inflammation, and with 0 indicating, e.g., no epithelial degeneration/necrosis or inflammation and with 4 indicating severe epithelial degeneration/necrosis and inflammation. **Statistics.** Statistical analysis was performed in GraphPad Prism using one-way analysis of variance (ANOVA), with results corrected for multiple comparisons. **Data availability.** Raw data are available from the corresponding author upon reasonable request.

**ACKNOWLEDGMENTS**

We thank Randy Albrecht for oversight of the conventional BSL3 biocollection facility. We thank Susan Stannes, Kaylee Murphy (Iowa Viral Vector Core), and Paul B. McCray, Jr. (University of Iowa), for making the AdV-hACE2 virus rapidly available to us. This work was partially supported by NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN27201400008C (F.K., A.G.-S.), Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 (F.K., A.G.-S.), NIAID grant R21AI157606 (L.C.), and a supplement to NIAID adjuvant contract HHSN272201800048C (F.K., A.G.-S.). This work was generously supported by the JPB foundation, the Open Philanthropy Project (grant 2020-215611 to A.G.-S.), and other philanthropic donations. The Icahn School of Medicine at Mount Sinai has filed patent applications for SARS-CoV-2 vaccines.

**REFERENCES**

1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Wang X, Shi HR, Zhu Y, Li B, Huang C, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen X, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LY, Yan B, Zhan XF, Wang YX, Xiao GF, Shi ZL. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 588:e636–e642. https://doi.org/10.1038/s41586-020-2012-7.

2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Ni P, Zhan F, Ma X, Wang D, Xu W, Wu W, Gao GF, Tan W, Team CNClAR. 2020. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733. https://doi.org/10.1056/NEJMoa2001107.

3. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YJ, Dai FH, Liu Y, Wang QM, Cheng JJ, Xu LJ, Holmes EC, Zhang YZ. 2020. A novel coronavirus associated with human respiratory disease in China. Nature 579:265–269. https://doi.org/10.1038/s41586-020-2202-3.

4. Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. 2019. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus. Front Microbiol 10:1781. https://doi.org/10.3389/fmicb.2019.01781.

5. Roper RL, Rehm KE. 2009. SARS vaccines: where are we? Expert Rev Vaccines 8:887–898. https://doi.org/10.1586/erv.09.43.

6. Amanat F, Krammer F. 2020. SARS-CoV-2 vaccines: status report. Immunity 52:583–589. https://doi.org/10.1016/j.immuni.2020.03.007.

7. Letko M, Marzi A, Munster V. 2020. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 5:562–569. https://doi.org/10.1038/s41564-020-0688-y.

8. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. 2020. Crystal structure of the 2019-nCoV spike receptor-binding domain with the ACE2 receptor. bioRxiv https://doi.org/10.1101/2020.02.19.956235.

9. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the pre-fusion conformation. Science 367:1260–1263. https://doi.org/10.1126/science.abb2507.

10. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181:281–292.e6. https://doi.org/10.1016/j.cell.2020.02.058.

11. Hoffmann M, Kleine-Weber H, Pöhlmann S. 2020. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell 78:779–784.e5. https://doi.org/10.1016/j.molcel.2020.04.022.

12. Jaimes JA, Millet JK, Whittaker GR. 2020. Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site. iScience 23:101212. https://doi.org/10.1016/j.isci.2020.101212.

13. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:270–280.e8. https://doi.org/10.1016/j.cell.2020.02.052.

14. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andries EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS. 2017. Immunogenicity and structures of a rationally designed pre-fusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A 114:E7348–E7357. https://doi.org/10.1073/pnas.1703041114.

15. Rathnasighe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, Garcia-Sastre A, Coughlan L, Schotsaert M, Uccellini M. 2020. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. bioRxiv https://doi.org/10.1101/2020.07.06.190066.

16. ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, Preiser W, Doerr HW, Chow VT, de Kruijf J, Peiris JS, Goudsmidt J. 2006. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 3:e237. https://doi.org/10.1371/journal.pmed.0030237.

17. Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, Mok CKP, Wilson IA. 2020. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science 368:630–633. https://doi.org/10.1126/science.abb7269.

18. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahan M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L, Fireser DS, Lugo LA, Kojic EM, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran T, Garcia-Sastre A, Capilviski D, Cheng AC, Kedzierska K, Vapalathi O, Hepojoki JM, Simon V, Krammer F. 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 26:1033–1036. https://doi.org/10.1038/s41591-020-0913-5.

19. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, Stoecker J, Xu L, Wu WC, Albrecht RA, Simon V, Martinez-Sobrido L, Moran T, Garcia-Sastre A, Krammer F. 2020. An in vitro microneutralization assay for SARS-CoV-2 serology and drug screening. Curr Protec Microbiol 58:e108. https://doi.org/10.1002/cpmc.108.
21. Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NR, Bailey AL, McCune BT, Fox JM, Chen RE, Alousssi BW, Turner JS, Schmitz AJ, Lei T, Shrihari S, Keeler SP, Fremont DH, Greco S, McCray PB, Perlman S, Holtzman MJ, Elbeddies AH, Diamond MS. 2020. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182:744–753.e4. https://doi.org/10.1016/j.cell.2020.06.011.

22. Sun J, Zhuan Z, Zheng J, Li K, Li Y, Liu D, Huang J, He J, Zhu A, Zhao J, Li X, Yi C, Chen R, Alshukairi AN, Chen Z, Zhen Z, Chen H, Xu J, Li F, Dai J, Chen D, Wen L, Zhuo J, Yang Y, Wang Y, Huang S, Dai J, Shi Y, Zheng K, Leidinger MR, Chen J, Li Y, Zhong N, Meyerholz DK, McCray PB, Perlman S, Zhao J. 2020. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182:734–743.e5. https://doi.org/10.1016/j.cell.2020.06.010.

23. Krammer F. 2020. SARS-CoV-2 vaccines in development. Nature 586:516–527. https://doi.org/10.1038/s41586-020-2798-3.

24. van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, P construed vaccine development enabled by prototype pathogen prepared-